4 citations,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
35 citations,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
12 citations,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
May 2016 in “The Journal of Sexual Medicine”
5 citations,
April 2021 in “Journal of Endocrinological Investigation” Higher DHT levels are linked to fewer hypogonadism symptoms in men with normal testosterone levels.
27 citations,
January 2017 in “Neuropsychopharmacology” The enzyme 5α-reductase is key in causing psychotic-like effects from sleep deprivation.
40 citations,
November 2020 in “JAMA Dermatology” Finasteride may cause suicidal thoughts and mental side effects, especially in young people with hair loss.
3 citations,
July 2018 in “African Journal of Urology” Finasteride before TURP reduces blood loss and slightly improves early postoperative quality of life.
April 2018 in “Expert Opinion on Drug Safety” Dutasteride is a safe and effective treatment for hair loss.
18 citations,
October 2017 in “Drug Design Development and Therapy” DA-9401 helps protect rat testis from finasteride damage.
72 citations,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
9 citations,
August 2019 in “Clinical genitourinary cancer” Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.
December 2023 in “Urogenital tract infection” Seminal bacteria can lower sperm quality in subfertile men.
30 citations,
October 2020 in “Nature Communications” Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.
8 citations,
June 2020 in “The Journal of Clinical Endocrinology and Metabolism” Taking 5α-reductase inhibitors with prednisolone can worsen its negative effects on metabolism.
6 citations,
December 2020 in “Dermatological reviews” COVID-19 may worsen with androgens; anti-androgen drugs could help.
15 citations,
October 2014 in “Hormone Molecular Biology and Clinical Investigation” Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.
25 citations,
May 2012 in “The Journal of Sexual Medicine” Finasteride reduces corpus cavernosum weight but doesn't affect erectile response in rats.
September 2023 in “Biology of reproduction” New testosterone analogs show promise for male contraception with better activity and potentially fewer side effects.
3 citations,
October 2019 in “Dermatologic Therapy” Hair loss in men is mainly caused by hormones and genes, and while current treatments can slow it down, they can't fully stop it.
11 citations,
March 2016 in “Translational Andrology and Urology” Nandrolone might increase muscle mass with fewer side effects than testosterone but could cause erectile dysfunction and needs more research.
98 citations,
February 2013 in “Journal of The American Academy of Dermatology” Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.
61 citations,
January 2019 in “American Journal of Clinical Dermatology” The cause of Frontal Fibrosing Alopecia is unclear, diagnosis involves clinical evaluation and various treatments exist, but their effectiveness is uncertain.
9 citations,
May 2021 in “Dermatologic Therapy” Possible link between androgens and COVID-19 severity; more research needed.
31 citations,
September 2015 in “BJUI” Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
28 citations,
June 2010 in “European Journal of Cancer” Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.
77 citations,
June 2015 in “Nature Reviews Urology” Some common medications can harm male fertility, but many effects can be reversed.
75 citations,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.